(Jan. 2 issue), 1 the combination of nivolumab and ipilimumab resulted in an unprecedented increase in overall and melanoma-specific survival, as compared with ipilimumab alone. We should be wary ...
The article by Doshi et al entitled “Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States” (JCO Clin Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback